Thyroid Nodule Detected
Palpated or incidentally found on imaging
All Pathways
Family MedicineDiagnostic
Thyroid Nodule Evaluation (ATA 2015)
Thyroid Nodule Evaluation (ATA 2015): Thyroid Nodule Detected → Initial Evaluation → TSH Level → Low TSH (Hyperthyroid) → Normal/High TSH.
Pathway Overview
13 steps
Algorithm Steps
13 total
01Start 02Action Initial Evaluation
History and TSH
- History: radiation exposure, family history thyroid cancer, compressive symptoms
- TSH level: first-line test for all thyroid nodules
- If TSH low: radionuclide scan (may be hot nodule)
- If TSH normal/high: proceed to ultrasound
03Decision TSH Level
Determines next step
04Action Low TSH (Hyperthyroid)
Consider autonomous nodule
- Radionuclide scan (I-123 or Tc-99m)
- Hot nodule: low malignancy risk, no FNA needed
- Treat hyperthyroidism (radioiodine, surgery, or antithyroid)
- Cold nodule: proceed to ultrasound/FNA
05Action Normal/High TSH
Thyroid ultrasound required
- High-resolution ultrasound of thyroid
- Evaluate nodule sonographic features
- Check for suspicious lymph nodes
- Measure nodule dimensions accurately
06Decision ACR TI-RADS Classification
Risk stratification by ultrasound features
- TR1 (Benign): cystic, no FNA
- TR2 (Not suspicious): No FNA regardless of size
- TR3 (Mildly suspicious): FNA if ≥2.5 cm
- TR4 (Moderately suspicious): FNA if ≥1.5 cm
- TR5 (Highly suspicious): FNA if ≥1 cm
07Outcome Observation
Repeat ultrasound in 12-24 months based on TI-RADS
08Action FNA Biopsy Indicated
Ultrasound-guided preferred
- TI-RADS 3: ≥2.5 cm
- TI-RADS 4: ≥1.5 cm
- TI-RADS 5: ≥1 cm
- Any size if suspicious nodes or vocal cord paralysis
- Repeat if non-diagnostic (up to 3 attempts)
09Decision Bethesda Cytology Result
6-category system
- I: Non-diagnostic (repeat FNA)
- II: Benign (follow-up US)
- III: AUS/FLUS (repeat FNA or molecular testing)
- IV: Follicular neoplasm (surgery or molecular)
- V: Suspicious for malignancy (surgery)
- VI: Malignant (surgery)
10Outcome Benign (Bethesda II)
Follow with ultrasound at 12-24 months, then as clinically indicated
11Action Indeterminate (Bethesda III/IV)
Molecular testing or surgery
- Molecular testing (ThyroSeq, Afirma): may avoid surgery if benign
- If suspicious molecular markers: surgery
- Diagnostic lobectomy if molecular not done
- Discuss options with patient
12Action Endocrinology Referral
Consider for complex cases
- Indeterminate cytology (Bethesda III/IV)
- Multiple nodules or MNG
- Hyperthyroidism requiring treatment
- Family history of thyroid cancer
13Warning Suspicious/Malignant (V/VI)
Surgical referral
- Endocrine surgery referral
- Total thyroidectomy or lobectomy (based on size, features)
- Staging workup if confirmed cancer
- Risk stratification for adjuvant RAI
- Path rejoins step 08Shared downstream outcome
- Path rejoins step 05Shared downstream outcome
Guideline Source
ATA Management Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Does not address molecular testing in detail
- Surgical indications simplified
- Active surveillance criteria abbreviated
- Does not address thyroid cancer staging/treatment
- Pediatric thyroid nodules require specialized evaluation
Applicable Regions
USAUUKEU
AU: AACE/ACE guidelines similar
UK: BST guidelines align with ATA
US: ATA 2015 guidelines with TI-RADS
Version 1Next review: 2027-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Thyroid Nodule Evaluation (ATA 2015)?
The Thyroid Nodule Evaluation (ATA 2015) is a diagnostic clinical algorithm for Family Medicine. It provides a structured decision tree to guide clinical decision-making, based on ATA Management Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer.
What guideline is the Thyroid Nodule Evaluation (ATA 2015) based on?
This algorithm is based on ATA Management Guidelines for Thyroid Nodules and Differentiated Thyroid Cancer (DOI: 10.1089/thy.2015.0020).
What are the limitations of the Thyroid Nodule Evaluation (ATA 2015)?
Known limitations include: Does not address molecular testing in detail; Surgical indications simplified; Active surveillance criteria abbreviated; Does not address thyroid cancer staging/treatment; Pediatric thyroid nodules require specialized evaluation. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Thyroid Nodule Evaluation (ATA 2015) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free